종양면역치료: 중세 암흑시대에서 르네상스시대로
Cancer Immunotherapy: The Dawn of the Renaissance after the Medieval Dark Ages
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cancer immunotherapy has come a long way since William Coley observed that a mixture of killed bacteria, or Coley’s toxin, inducedtumor regression. However, enthusiasm for cancer immunotherapy has changed to skepticism over recent decades due to itslack of efficacy, inconsistency, and significant toxicity. Of course, much of that skepticism was the result of a lack of understandingof the immune system. The recent expansion of our understanding of immunity and immune system and the success of new cancerimmunotherapies has raised hope that we can treat cancer effectively via immunotherapy or combination approach using immunotherapyand other cancer therapies. Indeed, there is no doubt that cancer immunotherapy is experiencing a renaissance. Here,I will briefly review the current status of various immunotherapies, including cytokine therapy, antibody therapy, cancer vaccines,and adoptive cell therapy, and then I will summarize the results of recent clinical trials using anti-immune checkpoint monoclonalantibodies.
Abstract
Cancer immunotherapy has come a long way since William Coley observed that a mixture of killed bacteria, or Coley’s toxin, inducedtumor regression. However, enthusiasm for cancer immunotherapy has changed to skepticism over recent decades due to itslack of efficacy, inconsistency, and significant toxicity. Of course, much of that skepticism was the result of a lack of understandingof the immune system. The recent expansion of our understanding of immunity and immune system and the success of new cancerimmunotherapies has raised hope that we can treat cancer effectively via immunotherapy or combination approach using immunotherapyand other cancer therapies. Indeed, there is no doubt that cancer immunotherapy is experiencing a renaissance. Here,I will briefly review the current status of various immunotherapies, including cytokine therapy, antibody therapy, cancer vaccines,and adoptive cell therapy, and then I will summarize the results of recent clinical trials using anti-immune checkpoint monoclonalantibodies.
참고문헌 (45)
- McCarthy EF, "The toxins of William B: coley and the treatment of bone and soft-tissue sarcomas", Iowa Orthop J, 26, pp.154~158 (2006)
- Hoption Cann SA, "Spontaneous regression: a hidden treasure buried in time", Med Hypotheses, 58, pp.115~119 (2002)
- Mellman I, "Cancer immunotherapy comes of age", Nature, 480, pp.480~489 (2011)
- Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
- Robert C, "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma", N Engl J Med, 364, pp.2517~2526 (2011)
- Brahmer JR, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", N Engl J Med, 366, pp.2455~2465 (2012)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Schadendorf D, "Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma", Eur Cancer Congr 2013 (ECCO-ESMO-ESTRO) (2013)
- Hamid O, "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", N Engl J Med, 369, pp.134~144 (2013)
- Hamid O, "Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM): American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2013; Chicago, IL", J Clin Oncol, 31(Suppl) (2013)
- Soria JC, "Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PD-L1)", Eur Cancer Congr 2013 (ECCO-ESMO-ESTRO) (2013)
- Wolchok JD, "Nivolumab plus ipilimumab in advanced melanoma", N Engl J Med, 369, pp.122~133 (2013)
- Mocellin S, "Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis", J Natl Cancer Inst, 102, pp.493~501 (2010)
- Royal RE, "Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma", Cancer J Sci Am, 2, pp.91~98 (1996)
- Crosbie EJ, "Cervarix: a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer", Expert Opin Biol Ther, 7, pp.391~396 (2007)
- Hanna E, "HPV vaccination with Gardasil: a breakthrough in women's health", Expert Opin Biol Ther, 6, pp.1223~1227 (2006)
- Cheever MA, "PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine", Clin Cancer Res, 17, pp.3520~3526 (2011)
- Vetsika EK, "Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001", Cancer Immunol Immunother, 61, pp.157~168 (2012)
- Liu TY, "Self-adjuvanting polymerpeptide conjugates as therapeutic vaccine candidates against cervical cancer", Biomacromolecules, 14, pp.2798~2806 (2013)
- Grossardt C, "Granulocytemacrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine", Hum Gene Ther, 24, pp.644~654 (2013)
- Zhang X, "A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer", J Urol, 187, pp.1071~1079 (2012)
- Yin W, "A novel therapeutic vaccine of GM-CSF", TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer, 2010, pp.28, 4937~4944
- Noguchi M, "Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine", Cancer Immunol Immunother, 62, pp.919~929 (2013)
- Li Y, "Prospects in adoptive cell transfer therapy for cancer", J Immunol Clin Res, 1, pp.1008~ (2013)
- Rayner AA, "Lymphokine-activated killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer", Cancer, 55, pp.1327~1333 (1985)
- Khayat D, "LAK cells and immunotherapy of cancer", Bull Cancer, 75, pp.3~7 (1988)
- Liu J, "Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokineinduced killer cells: a case report and review of the literature", Oncol Lett, 1, pp.955~958 (2010)
- Li W, "Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: a case report and review of the literature", Oncol Lett, 5, pp.1427~1429 (2013)
- Ma Y, "Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis", Cytotherapy, 14, pp.483~493 (2012)
- Hontscha C, "Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)", J Cancer Res Clin Oncol, 137, pp.305~310 (2011)
- Shi SB, "Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer", Tumori, 98, pp.314~319 (2012)
- Yuanying Y, "Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer", Cryobiology, 67, pp.235~240 (2013)
- Ren J, "Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences", Clin Transl Oncol, 15, pp.780~788 (2013)
- Rosenberg SA, "A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes", Science, 233, pp.1318~1321 (1986)
- Dudley ME, "Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients", J Immunother, 26, pp.332~342 (2003)
- Ratto GB, "A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma", Cancer, 78, pp.244~251 (1996)
- Morgan RA, "High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens", J Immunol, 171, pp.3287~3295 (2003)
- Morgan RA, "Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma", Hum Gene Ther, 23, pp.1043~1053 (2012)
- Robbins PF, "Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1", J Clin Oncol, 29, pp.917~924 (2011)
- Koehler P, "Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia", Adv Hematol, 2012, pp.595060~ (2012)
- Gill S, "CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road", Expert Opin Biol Ther, 14, pp.37~49 (2014)
- Ribas A, "Hepatotoxicity with combination of vemurafenib and ipilimumab", N Engl J Med, 368, pp.1365~1366 (2013)
- Hodi FS, "Multicenter, randomized phase II trial of GMCSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608", J Clin Oncol, 31 (2013)
- Lynch TJ, "Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB", IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study, 2012, pp.30, 2046~2054
- Reck M, "Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial", Ann Oncol, 24, pp.75~83 (2013)